Table 2.
Significantly associated compounds with clinical, cell-type, and COPD sub-phenotype variables.
| Variable | BAL | Plasma |
|---|---|---|
| Sex | 1 | 240 |
| Current Smoker | 249 | 7 |
| Age | 0 | 177 |
| Menopause | 0 | 0 |
| Neutrophil Count | 665 | 0 |
| Lymphocyte Count | 5 | 0 |
| Eosinophil Count | 0 | 4 |
| BAL Neutrophil Count | 0 | 4 |
| BAL Lymphocyte Count | 1 | 0 |
| BAL Eosinophil Count | 0 | 7 |
| BAL Monocyte Count | 1 | 0 |
| BAL Macrophage Count | 1 | 1 |
| Hemoglobin | 0 | 63 |
| Hematocrit | 0 | 80 |
| FEV1/FVC | 1230 | 0 |
| Emphysema, % | 791 | 2 |
| Chronic Bronchitis | 0 | 0 |
| Exacerbations/yr | 1 | 0 |
| FEV1 % | 8 | 0 |
Cells are populated with numbers obtained after testing all compounds, 7939 from BAL and 10,561 from plasma. Compound measures with >20% missingness in the raw data were modeled using tobit regression. Compound measures ≤20% missingness in the raw data were modeled using either beta, logistic, negative binomial, or linear regression (Table S2). Compounds were significant at p-value adjusted FDR (False Discovery Rate) <0.05 Emphysema, %: % Emphysema voxels (<−950 Hounsfield units) in lung CT image; FEV1 %: Postbronchodilator % predicted forced expiratory volume in one second; FEV1/FVC: Ratio of forced expiratory volume in one second to forced vital capacity; Exacerbations/yr: # of exacerbations in last year.